HDYO's Research Video Series – Excitement and Anticipation as PTC’s HD Drug Clears a Major Hurdle

This month's Research Video Series dives into the HD Buzz article, "Excitement and Anticipation as PTC’s Huntington’s Disease Drug Clears a Major Hurdle to Sprint Home." According to the article, "Votoplam, the daily pill from PTC Therapeutics, has met its primary endpoint in the PIVOT-HD clinical trial – it can lower huntingtin protein levels."

To read the complete article, visit https://en.hdbuzz.net/433/

The HDYO Research Video Series is sponsored by: Neurocrine Biosciences, Roche, Teva Pharmaceuticals, uniQure, Wave Life Sciences and the Griffin Foundation.